Bioventus Q2 revenue $153.2M (+4%), GAAP EPS $0.47; initiates strategic alternatives review

Bioventus Inc.

2026-Q2 EPS reported $0.52 revenue$285,297,000

Q2 revenue $153.2M (+4% YoY); GAAP EPS $0.47 vs $0.11; non-GAAP EPS $0.22 vs $0.21.
Pain Treatments revenue $81.7M (+11.5%); Surgical Solutions $50.4M (-4.5%); Restorative Therapies $21.1M (-2.4%).
Reaffirmed FY2026 guidance: net sales $600-610M, adjusted EPS $0.75-0.79, cash from ops $84-89M.
Board formed independent committee to evaluate strategic alternatives including sale, after unsolicited proposal.
Made $20M discretionary principal prepayment on term loan during Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.